The board of directors of Viva Biotech Holdings announced that Mr. REN Delin (Mr. Ren), an executive director of the company will begin serving as the general manager and chief executive officer of Viva Biotech (Shanghai) Ltd. and will cease to serve as the president of the company, effective December 1, 2023. Mr. Ren will continue to serve on the board of the company as an executive director and will remain as a member of Viva Shanghai's senior management team. He will serve as the general manager and chief executive officer of Viva Shanghai and will remain responsible for the overall management of the Group's contract research organization (CRO) and drug discovery functions.

The other roles and responsibilities previously held by Mr. Ren as president of the company Will be assumed by Mr. MAO Chen Cheney, the chief executive officer of the group and chairman of the company. The change in executive responsibilities will enable Mr. Ren to focus more of his attention to leading the Group's CRO and drug discovery businesses.